S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$40.29
$40.51
50-Day Range
$38.66
$40.39
52-Week Range
$18.34
$40.51
Volume
4.92 million shs
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.14

Chinook Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
5.6% Downside
$38.14 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$45,587 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.30) to ($3.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

Medical Sector

963rd out of 971 stocks

Biotechnology Industry

12th out of 14 stocks


KDNY stock logo

About Chinook Therapeutics (NASDAQ:KDNY) Stock

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.


KDNY Stock News Headlines

Chinook Therapeutics, Inc. (KDNY)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Expert Ratings for Chinook Therapeutics
Chinook Therapeutics (NASDAQ: KDNY)
Ben Stein FREE Report: How Americans Are RUINING Retirement
There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!
Why Are Chinook Therapeutics Shares Trading Higher Today
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Novartis Buys Chinook: M&A To Drive Future Growth
Chinook Shareholder Action Reminder
Chinook Shareholder Notice
Chinook Investor Alert
See More Headlines
Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Company Calendar

Last Earnings
8/07/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KDNY
Fax
N/A
Employees
214
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.14
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
-5.6%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

Net Income
$-187,870,000.00
Net Margins
-4,199.93%
Pretax Margin
-4,115.56%

Debt

Sales & Book Value

Annual Sales
$6.13 million
Book Value
$6.91 per share

Miscellaneous

Free Float
59,749,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.34
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Eric L. Dobmeier J.D. (Age 54)
    Pres, CEO & Director
    Comp: $972.19k
  • Mr. Tom FrohlichMr. Tom Frohlich (Age 47)
    Chief Operating Officer
    Comp: $627.44k
  • Mr. Andrew James King D.V.M.Mr. Andrew James King D.V.M. (Age 43)
    Ph.D., Chief Scientific Officer
    Comp: $651.48k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 63)
    Chief Financial Officer
  • Ms. Sukhi Thethy
    Sr. VP of Fin. & Accounting
  • Ms. Noopur Batsha Liffick
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Kirk D. Schumacher J.D.
    Sr. VP & Gen. Counsel
  • Ms. Jodi Jamieson
    Sr. VP of HR
  • Dr. Alan Glicklich M.D. (Age 60)
    Exec. Officer
  • Ms. Delphine Imbert Ph.D.
    Sr. VP of CMC & Technical Operations













KDNY Stock - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings
or view top-rated stocks.

What is Chinook Therapeutics' stock price forecast for 2023?

13 brokerages have issued twelve-month target prices for Chinook Therapeutics' stock. Their KDNY share price forecasts range from $32.00 to $43.00. On average, they predict the company's stock price to reach $38.14 in the next year. This suggests that the stock has a possible downside of 5.6%.
View analysts price targets for KDNY
or view top-rated stocks among Wall Street analysts.

When is Chinook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our KDNY earnings forecast
.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.13. The business earned $1.01 million during the quarter, compared to analyst estimates of $0.47 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $40.39.

How much money does Chinook Therapeutics make?

Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $2.90 billion and generates $6.13 million in revenue each year. The company earns $-187,870,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

The company employs 214 workers across the globe.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for the company is chinooktx.com. The company can be reached via phone at (206) 485-7241 or via email at investors@aduro.com.

This page (NASDAQ:KDNY) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -